Publications by authors named "I Schiefke"
Article Synopsis
- * A phase 3 trial is underway, where adult participants with confirmed NASH are randomly assigned to receive either resmetirom (80 mg or 100 mg) or a placebo, with primary goals of NASH resolution and improvement in fibrosis after 52 weeks.
- * In the trial's results, a significantly higher percentage of patients taking resmetirom experienced NASH resolution and fibrosis improvement compared to those on placebo, along with notable reductions in cholesterol levels, although some participants did report diarrhea.
Article Synopsis
- GI bleeding is a common complication of direct oral anticoagulants (DOAC), requiring immediate assessment of medication history and coagulation status before emergency procedures.
- Specific antidotes like idarucizumab and andexanet alfa are available for severe bleeding related to certain DOACs and are used after following proper emergency protocols.
- Resumption of anticoagulation is essential after successful hemostasis, considering the balance between bleeding and thromboembolic risks.
Background & Aims: Teduglutide is a Glucagon-like peptide-2 (GLP-2) agonist indicated for the treatment of patients with parenteral support (PS) dependent short bowel syndrome (SBS) with chronic intestinal failure (cIF). Its application is accompanied by a structured nation-wide home-care service program in Germany. We investigated care characteristics and outcome parameters in a clinical real-world observational setting.
View Article and Find Full Text PDFBackground & Aims: Based on positive results from small single center studies, granulocyte-colony stimulating factor (G-CSF) is being widely used for the treatment of patients with acute-on-chronic liver failure (ACLF). Herein, we aimed to evaluate the safety and efficacy of G-CSF in patients with ACLF.
Methods: In this multicenter, prospective, controlled, open-label phase II study, 176 patients with ACLF (EASL-CLIF criteria) were randomized to receive G-CSF (5 μg/kg daily for the first 5 days and every third day thereafter until day 26) plus standard medical therapy (SMT) (n = 88) or SMT alone.